Technology Transfer

MBM ScienceBridge GmbH is a technology transfer organization wholly owned by Georg-August University Göttingen public law foundation Germany.
Our goal is to evaluate, protect and actively commercialize intellectual property. As a service provider in the area of technology transfer we market innovations and intellectual property from nine different universities and research institutions in the state of Lower Saxony, Germany.
  1. Profile 1
  2. Profile 2
  3. Profile 3
  4. Profile 4
  5. Profile 5
  6. Profile 6
  7. Profile 7
  8. Profile 8
  9. Profile 9
  10. Profile 10

Diagnostics in Animal Health: Improved PCR Diagnostic for detection of Paratuberculosis (or Johne’s disease)

What we offer

Paratuberculosis or Johne's disease is a contagious, chronic and also fatal bacterial infection, which generally occurs early in life. The disease can exist undetected in a herd for many years. Scientists at the University of Göttingen developed an improved PCR diagnostic test for fast and early detection of Paratuberculosis.

HALLMARKS:
* New and improved PCR diagnostic test for fast and early detection of Paratuberculosis.
* Highly specific for MAP detection.
* Great sensitivity, whereby maintaining robustness ideal for point-of-care diagnostic.
* Successfully tested in feces, blood, milk, sperm and tissue samples.
* Rapid detection with qPCR technology – less time and less costs.
* Better performance than current ELISA tests.
* Higher sensitivity and less false negatives compared to current qPCR kits.

What we are looking for

USES:
*Diagnostic test for early MAP detection in:
Domestic livestock, including cattle, deer, sheep and goats.
Exotic ruminants (zoos).
Human patient samples due to high specificity and sensitivity.

We are looking for licensing partners.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Research Tool: Specific dipeptidyl peptidase 8 and 9 inhibitors

What we offer

Dipeptidyl peptidases (DPP) are essential for many biological processes and are therefore intensively studied within the research community. All available inhibitors the DPP IV family target the catalytic site of these enzymes. As the active site of all members of this family is highly conserved, current inhibitors always show residual activity against other DPP IV homologous. Our scientists developed new and pecific inhibitors of DPP 8 and 9, without inhibiting other members of the DPP IV family.

HALLMARKS
- New non-competitive and specific inhibition of DPP8 and DPP9.
- No background inhibition of DPP IV due to not targeting the catalytic site.
- No substrate-dependent loss of inhibition effect as with common competitive inhibitors.
- Penetration of active inhibitor through cell membranes achieved.

What we are looking for

We are offering this research tool for inlicensing to offer this unique peptide inhibitor to the research market.

Collaboration sought

  • Licence Agreement
  • Commercial Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Diagnostics: New genetic markers for transplant rejection

What we offer

Hematopoietic stem cell transplantation (HSCT) has recently become an important mainstay in oncology, particularly for the treatment of lymphoproliferative disorders and leukemia. Here, Graft-versus-host disease (GVHD) is a common complication in which the immune cells of the graft recognize the recipient (the host) as "foreign". The transplanted immune cells then attack the host's body cells. Our Scientists together with European academic partners have now developed new transplantation biomarkers for risk assessment and diagnosis of GVHD.

HALLMARKS:
- Novel genetic markers to predict and/or monitor risk of transplant rejection.
- Validated on microarray platform as well as with qPCR technology.
- Potential blood biomarker, current Skin Explant Technology only requires a very small and routinely taken skin biopsy of HSCT patients.

What we are looking for

We are looking for licensing partners for further development and commercialisation into blood-based diagnostic test.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Diagnostics & Imaging: New NIR fluorescent probes for improved tumor detection

What we offer

There is a great demand for the development of highly fluorescent and specific probes that enable a e.g. sensitive and early detection of malignancies and a separation from healthy tissue in a non-invasive way by in vivo imaging. Nanosized carrier systems or nanoparticles (NPs) are promising imaging tools as they exhibit several advantages, such as loading with multiple fluorophores, which results in highly intense fluorescent labels. We have co-developed new and powerful NP-encapsulated NIR fluorescence probes for an improved tumor detection.

HALLMARKS:
- New NP-encapsulated NIR fluorescence probes (NIR-NPs) with:
* High and stable fluorescence intensity without forming quenched aggregates.
* Large stokes shift, ideal for NIR-FRET imaging.
- New NIR-NPs of different sizes and surface modifications.
- Proprietary NIR-NPs are non-toxic (as tested in cell viability assays).

What we are looking for

USES:
- In vivo detection of different tissues, organs and cell types for diagnostics and guided surgery.
- Can be coupled to various targeting units (e.g. antibodies, peptides, oligonucleotides, drugs etc.).
- Probing of any disease targets trough choice of targeting unit.
- Probing for laboratory uses as research tool (NIR-Microscopy).

We are looking for licensing partners.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Diagnostics: Novel Biomarkers for the Diagnosis of Diabetic Nephropathy

What we offer

Diabetes has become the most common single cause of end-stage renal disease in the U.S., Europe and Japan with up to 40 per cent of diabetics developing diabetic nephropathy. In the U.S. the incidence of diabetic nephropathy has increased by 150% in the past 10 years. Thus, it is an urgent challenge to identify diabetes patients at the highest risk for developing diabetic nephropathy. Our scientists identified three different peptide biomarkers excreted in the urine of diabetic patients based on proteomics.

HALLMARKS:
- New urine biomarkers for nephropathies identified by proteomic approach.
- Robust procedure for the identification of proteins markers differentially excreted in the urine of diabetic patients.
- Urine biomarkers are indicators of tissue injury and may result in early diagnosis and prognosis.

What we are looking for

We are looking for licensing partners, who wants to further develop and commercialise the diagnostic potential of these urine biomarkers.

Collaboration sought

  • Research & Development
  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Research Tool: New animal model for Gastrointestinal Stromal Tumor (GIST)

What we offer

GIST is one of the most common mesenchymal tumors of the gastrointestinal tract. GIST has been named as an orphan drug disease. Our scientists developed a new animal drug screening model for GIST, which is caused by dysfunction of the Hedgehog pathway. This is the first immunological GIST mouse model with an aberrant Hedgehog signaling independent of Kit, demonstrating the importance of this particular pathway in GIST formation.

HALLMARKS:
- Novel GIST animal model caused by aberrant Hedgehog pathway independent of Kit mutations.
- Conditional gene knock-out of Ptch1, one of the key players within Hedgehog pathway.
- Severe gastrointestinal phenotype without affecting otherwise normal development.
- Good and effective breeding.

What we are looking for

USES:
- Excellent model for efficacy testing of new and potential therapeutics for GIST.

We are offering this animal model for in-licensing.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Research Tool: New animal model for arthritic diseases

What we offer

Arthritic diseases are conditions involving damages to the joints and/or cartilage. Traditional approaches for treatment of arthritis are typically not suitable for long-term use due to side effect issues. Our Scientists developed a new animal drug screening model for arthritic diseases, which is caused by dysfunction of the Hedgehog pathway. This is the first non-inflammatory mouse model with an aberrant Hedgehog signalling specifically in chondrocytes, demonstrating the importance of this particular pathway in arthritic indications.

HALLMARKS:
- Novel non-inflammatory arthritic animal model.
- Conditional gene knock-out in chondrocytes.
- Dysfunctional Hedgehog signaling causing hyperproliferation of chondrocytes, thus mimicking the known tumor-like proliferation phenotype of rheumatoid arthritis.
- Severe arthritic phenotype of spinal ankylosis (spinal malformation) without affecting otherwise normal development.
- Good and effective breeding.

What we are looking for

USES:
- Excellent model for efficacy testing of new and potential therapeutics for arthritis-related diseases.

We are offering this animal model for in-licensing.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Enzyme: Enzymatic method of producing Aldehydes, Alcohols and Esters from fatty acids

What we offer

1) Method of producing C6- and/or C9- Aldehydes, Alcohols and Esters based on a recombinant 9/13 divinylethersynthase (9/13 DES) to react with fatty acids hydroperoxides.

2) Method to produce plants with increased resistance against pathogens through a transgenic expression of the 9/13 divinylethersynthase.

HALLMARKS:
- Particularly stable production of 2E-isomers.
- Based on isolated 9/13 DES from garlic.

USES:
- Expression of fatty acid 9/13 DES in transgenic bacteria, yeast, cell or plant possible.
- Production of high value chemicals e.g. for the fragance, flavour, food, pharma industries.
- Production of high value intermediate chemicals e.g. for lubricants, surfactants, detergents, coatings, paints, biopolymers and/or plasticizers.

What we are looking for

We are offering this enzymatic technology for in-licensing.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Green Technology: New Bioparticle Analyzer for airborne microorganism

What we offer

Airborne microorganism like bacteria or spores can be found outdoors as well as indoors and are mostly clump together into large aggregates. If concentrations are too high they pose a healthy risk such as allergies or infections. Today's particle counters can only give a rough estimation of biological materials as they fail to detect microorganism in large aggregates. The new Bioparticle Analyzer combines efficient collection via impaction with an automated and fast detection and analyzing system using fluorescent label technology.

HALLMARKS:
- Automatic sampling and fast detection of airborne microorganism.
- High sampling efficiency for microorganism due to impaction on special silicones.
- Automatic detection and analysis of living organism using specific fluorescence markers.
- Fast detection of airborne microorganism in aggregates for the first time ever!

What we are looking for

USES:
- Can be used for indoor and outdoor measurements due to robustness and compact size
- Fast detection and analysis of bacteria, fungies, spores, pollen etc.
- Applications in environmental control, for controlling filter systems and for safety measurements in sensitive areas (laboratories, hospitals, airports, office buildings, old buildings etc.).

We are looking for licensing and developing partners.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager

Green Technology/Enzyme: New carbonic anhydrase enzyme from a marine source

What we offer

New isolated, cloned and characterized member of the alfa-class of carbonic anhydrase (CA) from a marine 'living fossil' showing a high resistance to high salinity, direct involvement in calcification process (CO2 fixation). CO2 is the most abundant greenhouse gas, its elimination crucial to slow down global warming. Nature already found a solution as CA enables cells to fix carbon, regulate pH and process ion transport or waste.

HALLMARKS:
- Resistance to high salinity
- Active even at low temperature and high temperature!
- Low sequence homology to existing CA (39% to human CA-II)

USES:
- CO2 elimination/fixation from exhausts or effluents
- Elimination of toxic carbon disulphide
- Synthesis of silicon dioxide
- Biosensors e.g. determination of pH or zinc

What we are looking for

We are offering this enzymatic technology for in-licensing.

Collaboration sought

  • Licence Agreement

Responsible

Mr Dr. Stefan Uhle

Patent Manager
back to list